Xenopat

www.xenopat.com

The orthotopic implantation of human tumors in mice allows Xenopat to provide services focused on assisting anticancer drug development and personalized oncologic treatment. Xenopat’s services focus on two main fields: Anticancer drug development. Xenopat offers to researchers and companies devoted to the development of new anticancer drugs, the most innovative tools available nowadays. Xenopat offers these researchers the OrthoXenoBank®, composed of several orthotopic patient-derived xenografts (orthotopic PDXs, orthoxenografts®) of different tumor types, characterized at histological and genetic levels and with different sensitivity to diverse chemotherapies. Personalized oncologic treatment. Xenopat offers to healthcare professionals and patients the most advanced technology in order to select the best treatment in their fight against cancer. Xenopat offers the possibility to generate an orthoxenograft® from a small fragment of the patient’s tumor. This mouse model will allow Xenopat to test several drugs and find, the best therapy for each patient.

Read more

Reach decision makers at Xenopat

Lusha Magic

Free credit every month!

The orthotopic implantation of human tumors in mice allows Xenopat to provide services focused on assisting anticancer drug development and personalized oncologic treatment. Xenopat’s services focus on two main fields: Anticancer drug development. Xenopat offers to researchers and companies devoted to the development of new anticancer drugs, the most innovative tools available nowadays. Xenopat offers these researchers the OrthoXenoBank®, composed of several orthotopic patient-derived xenografts (orthotopic PDXs, orthoxenografts®) of different tumor types, characterized at histological and genetic levels and with different sensitivity to diverse chemotherapies. Personalized oncologic treatment. Xenopat offers to healthcare professionals and patients the most advanced technology in order to select the best treatment in their fight against cancer. Xenopat offers the possibility to generate an orthoxenograft® from a small fragment of the patient’s tumor. This mouse model will allow Xenopat to test several drugs and find, the best therapy for each patient.

Read more
icon

Country

icon

City (Headquarters)

L'Hospitalet de Llobregat

icon

Employees

1-10

icon

Founded

2014

icon

Social

  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Chief of Scientific Office and Co - Founder

    Email ****** @****.com
    Phone (***) ****-****

Reach decision makers at Xenopat

Free credits every month!

My account

Sign up now to uncover all the contact details